Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...

Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without ...

Serum free light chain (sFLC) tests have advanced the prediction, diagnosis, and monitoring of plasma cell disorders. This webinar features two leading experts who will compare the performance of sFLC ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...

Researchers show for the first time that engineered human plasma B cells can be used to treat a disease -- specifically leukemia -- in a humanized animal model. The results mark a key step in the ...

For the roughly 30,000 Americans living with hemophilia and thousands more with rare enzyme deficiencies, treatment often ...

Researchers reveal critical mechanism behind idiopathic pulmonary fibrosis. Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...